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ABSTRACT: The International Society for Stem Cell Research has updated its Guidelines for Stem 
Cell Research and Clinical Translation in order to address advances in stem cell science and other 
relevant fields, together with the associated ethical, social and policy issues that have arisen since 
the last update in 2016. While growing to encompass the evolving science, clinical applications 
of stem cells, and the increasingly complex implications of stem cell research for society, the basic 
principles underlying the Guidelines remain unchanged, and they will continue to serve as the 
standard for the field and as a resource for scientists, regulators, funders, physicians, and 
 
 
members of the public, including patients. A summary of the key updates and issues is presented 
here. 
eTOC: 
The updated Guidelines for Stem Cell Research and Clinical Translation describe the ethical 
principles and best practices for basic, translational, and clinical research involving stem 
cells and human embryos. The updated Guidelines include new recommendations to address the 
recent scientific advances involving embryos, stem cell-based embryo models, chimeras, 
organoids, and genome editing.  
 
I. OVERVIEW OF THE GUIDELINES - EVOLVING WITH THE SCIENCE 
With any area of research, especially when it relates to humans and involves issues that may be 
considered ethically contentious, it is important to ensure it is subject to appropriate review and 
oversight. The stem cell field is one such area, and while some countries have relevant laws and 
policies governing how research and clinical applications are conducted, many jurisdictions 
around the world do not, or they have legislation with substantial gaps and ambiguities. Given 
this, carefully constructed guidelines can play a critical role, for scientists and clinicians 
conducting research and treating patients; for the public who may have hopes for or concerns 
about the research, may be funding it, and may become recipients of any treatments that result 
from it; and for governments that may have other more pressing demands on their capacity to 
develop laws and policies, and establish institutions to support them. 
 The International Society for Stem Cell Research (ISSCR) was founded in 2002 and rapidly grew 
to become the preeminent global, science-based organization dedicated to all aspects of stem 
cell research and its clinical translation. In addition to its role as a member-based organisation to 
promote scientific discourse and the sharing of data, early on the Society decided it should 
undertake the responsibility for developing guidelines to encourage high standards in practical 
and ethical aspects of relevant research and its applications.  
The first ISSCR Guidelines, published in 2006, had a major focus on human embryonic stem cells 
(hESCs), which had first been derived only 8 years earlier (Daley et al., 2007). By 2006 numerous 
hESC lines were being used by researchers in many countries, with substantial variation in both 
methodology and in the way their derivation and use was regulated. The 2006 Guidelines, which 
built upon the experience with earlier, more local efforts, reflecting underlying ethical principles 
for research, and proposed that institutions should establish stem cell research oversight (SCRO) 
committees. This was important to give regulators and the public confidence that hESC lines were 
being derived and used both sensibly and with sensitivity.  
In 2008 the ISSCR issued Guidelines focused on the clinical translation of stem cell therapies, 
essential if these were to realise their potential for regenerative medicine. Then, in 2016, the 
ISSCR updated and combined the previous two Guidelines, incorporated research and uses of 
induced pluripotent stem (iPS) cells, articulated ethical principles for stem cell research (such as 
integrity of the research enterprise, respect for patients and research subjects, and social and 
distributive justice), and expanded the purview to include research involving human embryos 
(Hyun et al., 2008; Daley et al., 2016). At the time, the latter was justified by: “Acknowledging 
 
 
that stem cell researchers engage in many forms of human embryo research that do not explicitly 
involve derivation or use of hESC lines, the guidelines broaden the scope of specialized review 
beyond the SCRO function to encompass all forms of human embryo research.” The … human 
embryo research … may not explicitly pertain to stem cells or stem cell lines, such as single cell 
analyses, genome modification, and embryo chimerism” (Daley et al., 2016). The 2016 Guidelines 
also proposed that, depending on the nature of the experiments to be conducted, review should 
entail a renamed “Embryo Research Oversight (EMRO)” process, signaling this wider remit.    
Over the last five years, there have been several key developments in the science related to the 
biology of stem cells and human embryos, to their potential and actual uses, including the 
application of genome editing, as well as an increase in examples of appropriate and 
inappropriate clinical applications. The pace, extent and potential importance of the new 
developments, and how they affect one other, have demanded a substantial rewrite and 
expansion of many sections of the ISSCR Guidelines. Key advances that the new 2021 Guidelines 
cover include: the culture of human embryos and stem cell-derived models of embryo 
development, both embryo-like entities and specific organ-like structures (organoids); 
chimeras; in vitro gametogenesis from cells; mitochondrial replacement techniques; somatic 
and germline genome editing; enhanced guidance for procurement of stem cell lines; and more 
robust clinical translation guidance (Isscr.org/guidelines). These new developments justify even 
more the inclusion of embryo research within the Guidelines, especially as ESCs or iPSC can 
provide both a test of methodology before moving to embryos and ESCs can provide subsequent 
tests of safety and efficacy.  Moreover, while the 2021 ISSCR Guidelines have evolved most 
clearly with respect to the underlying science, it also reflects evolving attitudes to what might 
be permissible, both in research and possible clinical applications, as well as to the importance 
of certain values, such as those of openness, transparency, fairness and equitable access to new 
therapies. This has also necessitated a fresh look at mechanisms ensuring appropriate review 
and oversight of research and clinical applications, where the Guidelines now place greater 
emphasis on the considerations that should be addressed rather than on specific committees.   
 
II. SCIENTIFIC AND ETHICAL REVIEW 
Robust mechanisms of review and oversight are essential to develop and maintain confidence in  
research and its applications. These help to ensure best practice with respect to the science and 
ethics, including obtaining informed consent from donors and patients. The updated Guidelines 
maintain rigorous independent review for human stem cell and embryo research, and for related 
research activities, but provide additional clarity, criteria, and practical guidance for its oversight. 
To emphasise both the purpose of the review and how it must be capable of evaluating the 
unique aspects of the science and the associated ethical issues of the research, along with 
broader concerns, the revised Guidelines now refer to it simply as a “specialized scientific and 
ethics oversight process”. They indicate that the review can take place at the institutional, local, 
regional, or national level, but encourage mechanisms to ensure consistency wherever possible. 
Moreover, although the Guidelines no longer recommend any specific named committee or 
process, they propose that it should be conducted by an established body, including an EMRO, 
 
 
ESCRO, SCRO or other committee, as long as this includes the relevant expertise appropriate for 
the topic being reviewed, as well as having generalists and lay members.  
As in previous iterations, the review process proposes several categories covering both research 
and its applications, but to accommodate advances in science and changing views, the Guidelines 
now subdivide some of these (see also Table 1):    
Category 1, which previously captured research exempt from review, now has two subcategories: 
1a: Research determined to be exempt from a specialized scientific and ethics oversight process after 
being assessed by the appropriate existing mandates and committees for laboratory research. This 
includes the routine culture of pluripotent stem cell lines, the reprogramming of human somatic cells, 
and research on stem cell culture systems that model specific stages of development or specific 
anatomic structures including organoids. Of course, as with all research actively involving the 
acquisition of human cells or tissues, appropriate consent must first be obtained from the donor or 
their legal representative. 
1b: This is a new sub-category, which includes types of research that need to be reported to the entity 
responsible for the specialized scientific and ethics oversight process, but, at the discretion of this 
entity, and subject to regulations and policies in the relevant jurisdiction, the research need not 
normally be subject to further or ongoing review. This covers projects that may be of no public concern 
in themselves, but that have the potential to lead to work that might, such as in vitro chimeric embryo 
research and in vitro gametogenesis where there is no intent to generate a human embryo.  
Category 2. The principles covering review under this category remain the same; however, this 
now includes additional types of research. It is research under this category that will clearly give 
the majority of work for the specialized scientific and ethics oversight process (see Table 1). It 
includes research that the process might conclude is permissible, perhaps with conditions 
applied, and as long as it also complies with regulations and policies in the relevant jurisdiction.  
Category 3, as before, is concerned with types of research that are prohibited. However, it has 
now been revised and subdivided into two categories to make a distinction between the reasons 
for prohibition: 
3a: Research activities currently not permitted because the approaches are not yet considered safe 
enough and/or raise ethical issues that are unresolved. Examples include research on human germline 
genome editing, mitochondrial genome editing, and the use of human gametes differentiated from 
human stem cells for fertilization and human reproduction. 
3b: Prohibited research activities that should not be pursued because of broad international consensus 
that such experiments lack a compelling scientific rationale and are widely considered to be unethical. 
This category includes human reproductive cloning, breeding chimeras that may contain 
human gametes, and transfer of human embryos to an animal uterus, among other lines of 
research. 
 
III. NOTABLE NEW GUIDANCE   
(i). Embryo culture and embryo models 
 
 
Two papers were published in 2016, around the time the previous version of the Guidelines was 
published, showing that it was possible to culture intact preimplantation human embryos up to 
the equivalent of 13-day post-implantation embryos, i.e. shortly before gastrulation which begins 
around 14 days in humans (Shahbazi et al., 2016; Deglincerti et al., 2016). The methods were 
based on those developed about two years earlier for mouse embryos, with evidence that these 
could undergo gastrulation. It has been possible to culture macaque embryos up to about 20 
days, well beyond the 14-day equivalent and gastrulation in human embryos (Niu et al., 2019; 
Ma et al., 2019). This has not been done with human embryos, because of the “14-day rule” that 
has been adopted in some guidelines, including those from the ISSCR, and enshrined in law in 
several countries, such as in the UK since 1990. There is now building pressure to extend or even 
abolish this limit in order to permit research into very important stages of human embryo 
development, about which we know little, but where many cases of miscarriage or birth defects 
are likely to have their origins (Williams and Johnson, 2020; Hyun et al., 2021; McCully, 2021). 
Other reasons for extending the culture period include: (i) To provide control material against 
which to validate stem cell-based embryo models (see below), which, if successful, would reduce 
the future need to carry out some types of research directly with human embryos; and (ii) to 
enable more thorough analysis of safety and efficacy of a wide range of methods either currently 
employed in IVF or that could be introduced, notably mitochondrial replacement techniques, 
heritable human genome editing, and in vitro-derived gametes (see below) (Clark et al., 2021).      
Consequently, the in vitro culture of any intact human preimplantation embryo beyond 14 days 
or formation of the primitive streak (whichever occurs first) is now removed from Category 3. 
Instead, all research involving culture of intact human embryos is subject to Category 2 review, 
but balancing the potential value of this research with the ethical and societal concerns raised by 
it, and taking into account the social responsibility to be transparent throughout the process, the 
guidelines recommend that before a committee responsible for the specialized scientific and 
ethics review process may even consider applications for human embryo research beyond 
formation of the primitive streak or 14 days, national academies of science, academic societies, 
funders, and regulators should lead public conversations on the scientific significance as well as 
the societal, moral, ethical and policy issues raised by allowing such research (Recommendation 
2.2.2.1). This public dialogue should help provide guidance on what types of experiments might 
prove permissible.  
One of the guiding principles of the review process with respect to human embryos is that there 
should be no valid (and existing) alternative way of obtaining the same information. This leads to 
the topic of embryo models. In parallel to the development of embryo culture systems, stem cell-
based embryo models have rapidly advanced since the 2016 Guidelines and two distinct types 
are now recognized by the new Guidelines:    
(a) Non-integrated models (Category 1b): These experimentally recapitulate some, but not 
all, aspects of the early postimplantation embryo, and would include gastruloids. These lack 
extraembryonic cells types and may have only a partial anterior-posterior embryonic axis and would 
therefore have no reasonable expectation of achieving substantial development in vitro, or in vivo if 
any attempt was made to transfer them to a human or animal uterus. These were previously part of 
Category 2 when no distinction was made between non-integrated and integrated models. 
 
 
(b) Integrated models (Category 2): These models, which include ‘blastoids’ derived entirely from stem 
cell lines, contain relevant embryonic and extra-embryonic cell types, and could potentially achieve 
the complexity by which they might realistically undergo further integrated development if cultured 
for additional time in appropriate conditions or, theoretically, if transferred to a uterus. After review 
by the specialized scientific and ethics oversight process, and if permission is given, these could be 
maintained in culture for the minimum time necessary to achieve the specific scientific objectives. 
Any absolute time limit, such as 14 days, would not make sense, in part because these entities would 
already have had an extended period in culture as stem cells, but also because they are not bona fide 
embryos. Despite what may eventually prove to be a close resemblance to the latter, they are very 
unlikely to possess typical epigenetic marks, and may miss specific cell states required for viable 
embryogenesis. In addition, because they are derived from stem cell lines, this allows generation of 
many genetically identical blastoids, which has experimental advantages; but this would be another 
potential route to ‘human reproductive cloning’, which is not permissible for any reason. Thus, 
transfer to a human or animal uterus is not permitted (Category 3B). Nevertheless, such models 
might well reduce the need for genuine human embryos in some types of research. More detailed 
discussion of embryo culture and embryo models can be found in the white paper by Clark et al 
elsewhere in this issue (Clark, et al., 2021). 
(ii). In vitro-derived gametes  
While not yet achieved, there has been notable progress in research aimed at generating 
functional gametes from stem cells, either entirely in vitro or after a combination of in vitro 
culture followed by incorporation into gonads or gonadal-like structures in vivo. This progress is 
most pronounced with animal models, notably mice, where in vitro-derived sperm or oocytes 
have been obtained using directed differentiation of pluripotent stem cells followed by co-
culture with testicular or ovarian cells, respectively, or in a range of mammals from the mouse to 
macaques, where spermatogonial stem cells can be cultured, genetically manipulated, and then 
introduced into the testis to undergo spermatogenesis. Moreover, at least a proportion of 
gametes derived using these protocols have been shown to be capable of giving rise to zygotes 
after fertilization and then to embryos and live born animals. There are many reasons for trying 
to achieve this in humans, notably: (i) As a way to research and understand human germ cell and 
gamete development, which has been very difficult to study; (ii) As a means to restore fertility, 
e.g. after cancer radiotherapy or chemotherapy; (iii) To provide a supply of gametes, notably 
oocytes, for a wide range of studies on early embryos, reducing the need for gamete donors; and 
(iv), to provide a route to heritable human genome editing (see below). The revised Guidelines 
hold that research conducted in vitro involving the derivation of human sperm or oocytes can 
proceed without review by a specialized oversight process, as long as no attempt is made to 
fertilize them or otherwise create embryos. However, because of the likely interest and concern 
from both the public and regulators, this research has been placed in Category 1B. If, however, 
the research entails testing gametes derived after any period of in vitro culture by fertilization 
and/or the creation of embryos, this must be subject to review, approval, and ongoing 
monitoring, as appropriate, through a specialized oversight process capable of evaluating the 
unique aspects of the science and the associated ethical issues. This latter research is therefore 
firmly in Category 2.  
    
(ii). Organoids    
 
 
Methods to derive and culture specific cell types, tissues and organoids from stem cells have also 
improved since 2016, with a greatly expanded repertoire of sometimes quite sophisticated 
structures now being studied. Most of these raise few ethical concerns. However, extensive 
coverage of the topic by the media prompted discussions during the process of revising the 
Guidelines whether work using central nervous system (CNS) organoids warranted review 
through the specialized oversight process. These discussions included the question of whether 
CNS organoids may achieve consciousness or perceive pain. However, at this time, there is no 
biological evidence to support such concerns. Both require a level of complexity and maturity, 
and connections with relevant sensory systems, that are not achieved in any current culture 
system. Consequently, all organoid research is currently in Category 1A. Nevertheless, the ISSCR 
and future Guidelines update committees should review this topic as science advances and 
additional information becomes available (National Academies of Sciences, Engineering, and 
Medicine, 2021). 
(iii). Human-Animal chimeras 
There are many reasons why it can be useful to generate animals containing human cells or 
tissues. These notably include assaying the potential of human stem cells in an in vivo situation; 
creating better animal models for studying human disorders and ways of treating these; and even 
perhaps the generation of organs and tissues for transplantation. This is a complex area where 
concerns vary according to type and stage of non-human animal used as recipient/host and the 
specifics of the human cells, notably whether they have a broad or narrow potential (which may 
only be discovered on carrying out the experiments). Additional methods, such as ‘blastocyst 
complementation’ can also be used, at least in theory, to allow human cells introduced into early 
embryos to completely replace a specific tissue or even, perhaps, to confine their likely 
contribution to only this tissue in the resulting animal. As with other methods outlined in this 
article, there have been significant advances made over the last five years in making and 
analysing such chimeras, and these are very likely to continue apace.   
Relevant areas of potential research fall into almost all of the review Categories. If the experiment 
involves the transfer of a few stem cells into a postnatal animal, then this would not require any 
special review outside that provided for animal research generally; i.e. it would be Category 1A. 
Chimeric embryo research in which pluripotent human stem cells are transferred into 
mammalian non-human embryos and cultured in vitro would be Category 1B. This is a new 
requirement making these experiments reportable, more because they might be of public 
interest, rather than them raising unique ethical concerns. A recent example of this involved 
introducing ‘expanded potential’ human pluripotent stem cells into macaque blastocysts that 
were then cultured to primitive streak stages, where they showed a modest contribution (Tan, 
et al. 2021). If such experiments involved the transfer of the embryos into the uterus of a non-
human animal, this would fall under Category 2, because it would clearly demand consideration 
by the special review and oversight process (although this would exclude transfer into greater 
and lesser apes, which is prohibited.) A particular concern arises if there were a substantial 
contribution of human cells to the CNS of the animal. It will be difficult to predict how brain size 
and connections to animal sensory and motor systems will affect phenotypes. Therefore, such 
experiments should proceed in a careful step-wise manner, with review at critical stages, paying 
 
 
particular attention to behaviour and animal welfare issues if any of the chimeras are brought to 
term (National Academies of Sciences, Engineering, and Medicine, 2021). Finally, transfer of such 
chimeras into a human uterus, or breeding chimeric animals where there is a chance they have 
human gametes, are prohibited and clearly fall into Category 3B. For more about this topic and 
the discussions around it, please see Hyun et al., 2021 in this issue. 
(iv). Mitochondrial replacement techniques 
Mitochondrial replacement techniques (MRT) involve the transfer of nuclear genetic material, 
notably the meiotic spindle with chromosomes attached before fertilization, or both the 
maternal and paternal pronuclei at the zygote stage after fertilization, into an enucleated oocyte 
or zygote at the equivalent stages. (A third method, polar body transfer, might also be feasible, 
but published data on this are limited.) This has the effect of swapping the cytoplasm, which 
contains the mitochondria with their DNA (mtDNA), in order to effectively replace pathogenic 
mtDNA causing serious disease with normal mtDNA. This should allow a woman (mitochondria 
are only inherited via the mother) at risk of having an affected child to have a genetically-related 
child free from mitochondrial disease. The child would have contributions as normal from the 
mother’s nuclear DNA as well as that from the father, but mtDNA from the oocyte donor. To 
date, the the UK is the only country to actively permit in law the use of MRT specifically to avoid 
serious mitochondrial disease. Regulations were passed in 2015 by the UK Parliament and 
detailed guidelines were then drawn up and adopted by the regulator, the Human Fertilisation 
and Embryology Authority (HFEA), who granted the first licence to carry out the procedures to 
researchers in Newcastle in 2017. However, the techniques are now being used elsewhere, and 
not just to avoid mitochondrial disease, but as a way to overcome female infertility where 
preimplantation embryos generated by in vitro fertilisation (IVF) repeatedly fail to develop. There 
is no established explanation for why MRT should work for the latter women, therefore 
application of these methods in such cases is speculative. The revised Guidelines therefore limit 
the clinical use of MRT to those at high risk of transmitting serious mtDNA-based diseases to their 
offspring and when no other treatments are acceptable. Such use now falls under Category 2, 
whereas previously MRT was in Category 3. Due to inadequate pre-clinical data and scientific 
rationale, the Guidelines also recommend not using MRT for unexplained female infertility 
associated with poor oocyte/embryo quality. Notably, the Guidelines also encourage more 
research to refine and assess the safety and efficacy of MRT, in particular to address a potential 
problem of ‘reversion’, which was seen in preclinical data involving the culture of ES cells derived 
from MRT embryos, where the maternal mtDNA may come to predominate again (Greenfield, et 
al., 2017)    
(v). Genetic alteration of the mitochondrial genome (mtDNA) 
Genome editing of mtDNA provides another approach to allowing women at risk to have a 
genetically-related child free from mitochondrial disease. This could be done in addition to the 
use of MRT to eliminate the possibility of any carryover of the abnormal mtDNA, by simply cutting 
and destroying the maternal mtDNA haplotype; or it could be carried out as an alternative, either 
to reduce the proportion of mutant mtDNA in cases of heteroplasmy or to correct the relevant 
sequence in the mtDNA. Research involving editing of mtDNA in human embryos would be 
 
 
permitted under Category 2, however, transferring them into a human uterus for gestation is 
currently not permitted. The latter is placed in Category 3A because there is scientific rationale 
behind this possible approach, but as yet insufficient preclinical data regarding safety and 
efficacy; indeed, in countries with relevant legislation, this is currently illegal. Ideally, there would 
also need to be demonstrable public support to use the methods clinically in any jurisdiction 
contemplating clinical use of these methods, which would be a form of heritable genome editing, 
albeit of the mitochondrial and not nuclear genome.  
(vi). Human genome editing  
(a) Heritable genome editing (or germline genome editing for reproductive purposes). This 
remains a prohibited research activity, because currently the methods are neither 
sufficiently safe nor efficient. However, because there are defensible reasons for pursuing 
this line of research, this has been placed in Category 3A. These reasons may include 
situations where correcting a deleterious gene variant is the only way that prospective 
parents may have a genetically-related child (see the Commission Report from the National 
Academy of Medicine, National Academy of Sciences, and the Royal Society, 2020). 
However, any decision to proceed with clinical use of the methods will be dependent not 
only on substantial preclinical assessments as to safety, efficiency and efficacy, but also on 
appropriate policies, regulation, and oversight being in place. It will also require meaningful 
public engagement, political support, and proper oversight within the relevant jurisdiction.  
The Commission report provides guidance for initial clinical uses of human germline genome 
editing once the technical, safety, and ethical issues are resolved, including a case-by-case 
evaluation of scientific methods and the societal and ethical issues associated with any 
proposed use. The revised ISSCR guidelines also encourage the development of a 
comprehensive regulatory and ethical framework for overseeing heritable human genome 
editing that builds on the existing regulatory frameworks for new biotechnologies, the 
practice of medicine, and describes a set of principles that should be followed. The report 
from the WHO’s Expert Advisory Committee on Developing Global Standards for Governance 
and Oversight of Human Genome Editing, which is due to be published in May 2021, provides 
a Framework for Governance, as well as other material that should be of benefit when 
considering not just Heritable Human Genome Editing, but also Somatic Genome Editing (see 
below).   
(b) Non-heritable (non-reproductive) germline genome editing. It follows that preclinical 
research to optimize methodologies and minimize potential harms associated with any 
heritable application is encouraged. Such research, if it involves human embryos (either 
surplus embryos from IVF that are not wanted for reproduction and have been donated for 
research, or embryos that are created specifically for research), would be placed in Category 
2 and subject to robust review and oversight, as would any basic research involving human 
genome editing to explore, for example, the role of specific genes during early 
embryogenesis. The use of other germline cells for this research, notably pluripotent stem 
cells and gamete progenitors, including spermatogonial stem cells, would fall under 
 
 
Category 1A or 1B, respectively, unless these were being used to create embryos, when it 
would move to Category 2.  
(c) Somatic genome editing. The Guidelines also provide new guidance on somatic genome 
editing research and applications, including in utero genome editing and stem cell-based 
interventions. Notably, clinical research involving in utero stem cell-based interventions or 
genome editing involves two patients, the pregnant woman and the future child, and should 
be undertaken, preferably in the context of a well-designed clinical trial, only when it offers 
the prospect of a benefit greater than that of post-natal interventions, does not pose 
excessive risk to the pregnant woman, and where there is institutional capacity for autopsy 
(in the case of miscarriage or stillbirth) or follow-up (in the case of live birth). 
Basic and preclinical research on somatic genome editing, which is conducted in vitro and/or 
in animal models, should not require specialised review and oversight and falls into Category 
1A. Clinical research and applications of somatic genome editing should largely be covered 
by existing review and oversight mechanisms governing gene therapy (Doudna, 2020). 
However, detailed and additional considerations are provided within a new Appendix to the 
ISSCR Guidelines. The WHO’s Expert Advisory Committee on Developing Global Standards 
for Governance and Oversight of Human Genome Editing also considers somatic genome 
editing. It does so because, as well as offering potential treatments, applications of somatic 
genome editing could be open to abuse and malpractice, and the topic also raises issues of 
social and distributive justice. The WHO Committee’s Report should again provide an 
authorative reference point for considering governance in this area.     
  
IV. PROCUREMENT OF CELLS AND TISSUES / DERIVATION OF STEM CELL LINES  
The revised ISSCR Guidelines provide a new three-tiered system to streamline the review process 
for the procurement of banked and historical cell lines, while maintaining a rigorous review 
process for the procurement of embryos and gametes for stem cell research. In each case, 
procurement should follow generally accepted principles of research ethics, including those 
related to donor consent, relevant laws, policies, and regulations in the jurisdiction, as well as 
the principles laid down in the Guidelines. 
• Tier 1: The procurement and use of banked and historical human cell lines is permissible if the 
materials have been deposited according to contemporaneous ethical and regulatory standards, 
and are distributed consistent with the original consent given for their use, along with additional 
provisions spelled out in the Guidelines. Notably, the latter include that Tier 1 cell lines should not 
be used for reproductive purposes, e.g. to create embryos from in vitro-derived gametes. 
• Tier 2: The procurement of fresh human somatic cells and tissues for the purposes of stem cell 
research should be reviewed by existing review and oversight committees, bolstered by relevant 
stem cell expertise. 
• Tier 3: The procurement of human gametes and embryos that are destined for use in human 
embryo research and stem cell research must be reviewed through the specialized oversight 
process as outlined in the Guidelines. This should include monitoring of the practices of donor 
 
 
recruitment to ensure that the decision of women to donate their oocytes (or embryos) is free of 
undue inducement and exploitation. 
 
The Guidelines also stress that any review and oversight process must ensure that vulnerable 
individuals and populations are not exploited. There must be no undue inducements or other 
unacceptable influences for the provision of human cells and tissues. In addition, the Guidelines 
recommend that cell and tissue donors should be able to choose whether they wish to receive 
incidental findings, such as the presence of a risk allele for a genetic disease or cancer, and that 
this should be clear in the consent process. Provenance of stem cell lines must be easily verifiable 
by access to relevant documents such as material transfer and licensing agreements and data 
demonstrating the identity of the cell line and uses allowed under the original informed consent 
(Isasi, et al. 2019). However, due to advances in and increasing ubiquity of genomic sequencing, 
researchers are strongly encouraged to maintain confidentiality when sharing genomic data that 
has the potential to connect donors and family members with de-identified cells and tissues 
(Isasi, et al. 2014; Knoppers, et al. 2011). 
Overall, the revised Guidelines provide more realistic recommendations on the derivation and 
banking of new lines that will protect donors, facilitate research by making it clearer what is 
permitted or not, and ease compliance for companies developing stem cell-based products. 
 
V. CLINICAL TRANSLATION 
The number of clinical trials and other interventions involving stem cells has increased 
significantly over the last 5 years, as have the number of inappropriate uses and exaggerated or 
false claims. Given the knowledge gained regarding what works well, what might not, and what 
is lacking, considerable effort was taken to modernize the recommendations for clinical 
translation and regulator approval in the revised Guidelines.  
(i) To facilitate bona fide treatments, the Guidelines now: 
• Include a new recommendation on sex as a biological variable (although this must apply also to 
basic and preclinical research). 
• Support the use of accelerated approval pathways based on surrogate or intermediate endpoints.  
• Encourage robust post-market surveillance systems in jurisdictions with conditional approval 
pathways.  
• Encourage health systems and payers to establish a process for evaluating the health benefits and 
economic value of stem cell-based interventions.  
(ii) New or updated recommendations are also made in the Guidelines to curb premature or 
inappropriate commercialization of cell therapies; consequently they:  
• Include an updated recommendation to forcefully caution against the premature 
commercialization of unproven stem cell-based interventions.  
 
 
• Adopt international standards for defining stem cell-based products as drugs or advanced therapy 
medicinal products (ATMPs) if such products have been substantially manipulated or are provided 
for non-homologous uses. This standard aligns with the U.S. FDA, the EMA, and Australia’s TGA.  
• Include new recommendations on regulations authorizing stem cell-based products, including the 
demonstration of substantial evidence of effectiveness in appropriately powered, well-controlled 
clinical trials, with statistically significant findings.  
• Narrow the types of stem cell-based products eligible for the medical innovation pathway that is 
aligned with international regulatory standards, including the US FDA.  
• Strengthen the recommendation on patient registries to clarify their use as a tool for disease 
histories and tracking long-term patient outcomes. The recommendation also notes that registries 
are not adequate substitutes for randomized controlled trials to demonstrate the safety and 
efficacy of products for marketing authorizations. Indeed, in some cases the registries seem to be 
used merely as a form of advertising, a practice that is at best misleading and goes against a duty 
of care for patients.  
 
VI. CONCLUSIONS 
It is hoped that these revised Guidelines are sufficiently forward-looking to capture the science 
surrounding human stem cell and embryo research, and its social and regulatory context, not just 
now, but also its likely trajectory over the next several years. It is notoriously difficult to predict 
how any of these might change and over what time-scale. This has been evident over the last five 
years, with many advances and altered opinions necessitating an extensive set of revisions. 
Neither the field nor those involved in it should remain static; consequently, the Guidelines will 
need to evolve and should be read with this in mind. Nevertheless, the principles underlying the 
Guidelines, which have not changed from earlier versions, will endure. Therefore, whether 
carrying out research or treating patients, adhering to these principles should always be the 
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TABLE 1: Categories of Research 
 
CATEGORY 1 CATEGORY 2 CATEGORY 3 
1A – Exempt from review by 
a specialized oversight 
process 
- Most in vitro 
pluripotent stem cell 
research 
- Most in vitro 
organoid research 
- Transfer of human 
stem cells into 
postnatal animal 
hosts 
2 – Reviewed by a 
specialized oversight process 
- Procurement of 
embryos, or gametes 
for the creation of 
embryos, for in vitro 
research  
- Derivation of cell 
lines from human 
embryos 
- Genetic alteration of 
embryos or gametes  
- In vitro culture of 
human embryos for 
research  
3A – Not allowed: currently 
unsafe 







embryos into a 
uterus  
- Using gametes 
differentiated from 




1B – Reportable, but not 
typically reviewed by a 
specialized oversight process 
- Non-integrated stem 
cell-based embryo 
models 
- In vitro culture of 
chimeric embryos 
(human cells into 
non-human embryos)  
- In vitro 
gametogenesis 
without fertilization 
or generation of 
embryos 
- Human cells 
transplanted into 
nonhuman embryos 
that are gestated in a 
non-human uterus 
- Integrated stem cell-
based embryo 
models 
- Transferring human 
embryos following 
MRT into a human 
uterus 
3B – Not allowed: lacks 
compelling scientific 
rationale and/or is ethically 
concerning  








where there may be 
human germ cells. 
- Transferring human-
animal chimeric 




- Transferring human 
embryo(s), 
irrespective of 
origins, to an animal 
uterus 
Legend: A brief summary of the categories of research from the 2021 ISSCR Guidelines for Stem 




Table 2: THE PROCESS 
The ISSCR Board established the Guidelines Revision Task Force, comprising 45 members (the authors of 
this article), in June 2019. This was carried out in consultation with the Chair, who had been identified 
earlier, and involved discussions with other key individuals to help ensure breadth and balance. It was felt 
important to ensure that the new Guidelines be developed by drawing on a wide range of perspectives, 
discplines, and backgrounds, and that it was not just informed by science, but by ethical, legal, regulatory, 
clinical, and commercial viewpoints.    
Overview of structure  
A Steering Committee comprising ten members was established, each with substantial experience in 
aspects of stem cell research and in formulating guidelines. The Committee included the Chair of the task 
force responsible for the previous revision of the ISSCR Guidelines in 2016. The Steering Committee 
oversaw the process via frequent online meetings and one in-person meeting in San Francisco in February 
2020. The latter was an important occasion to establish the topics that would provide the focus of many 
of the revisions as well as providing a direction of travel for some of these. 
 
 
The Task Force was also supported throughout by members of the ISSCR Policy and Outreach Teams, 
notably by Eric Anthony, Jack Mosher, and Glori Rosenson, who deserve much of the credit for the revised 
Guidelines.    
The task force was divided into four Working Groups, each chaired by two Steering Committee members, 
with globally diverse expertise, and focused in four key areas: 
(i) Genome editing and MRT 
(ii) Embryos, embryo models and gametogenesis research 
(iii) Organoid and chimera research 
(iv) Regulatory, pricing, and access issues 
The Working Groups and Steering Committee met often over the course of 15 months to draft and revise 
the Guidelines,  
An early draft of the revised Guidelines was reviewed in May 2020 by the ISSCR Ethics, Public Policy, 
Clinical Translation, and Industry committees, and then by the ISSCR Board in June 2020. This led to a 
number of revisions and updates. The next draft was subject to extensive and international external peer 
review during September and October, 2020, which resulted in additional modifications. Based on this 
version, the main revisions being made in the Guidelines were then presented to ISSCR members in four 
separate briefings during November 2020. Further revisions and updates were then incorporated, before 
a more complete draft was given to the ISSCR Board, gaining their approval in December 2020.  As the 
final version was being prepared, between then and now, some additional changes and updates were 
made, but in each case the wording was assessed by both the relevant Working Group and the  Steering 
Committee. 
 
Legend: An overview of the process undertaken to develop and review the 2021 Guidelines 
update.  
 





All research that (a) involves preimplantation stages of human development, in vitro 
human embryo culture, derivation of new embryo-derived cells or lines, integrated stem 
cell-based embryo models, or (b) entails the production of human gametes in vitro when 
such gametes are tested by fertilization or used for the creation of embryos, shall be 
subject to review, approval, and ongoing monitoring, as appropriate, through a specialized 
oversight process capable of evaluating the unique aspects of the science and the 
associated ethical issues. 
2.1.2 
The specialized scientific and ethics oversight process must include an assessment of the 
scientific rationale and merit of research proposals, the relevant expertise of the 





The committee or body conducting the specialized scientific and ethics oversight process is 
responsible for (a) advising researchers on the categorization of research (see 
Recommendation 2.1.5), (b) determining whether a research proposal constitutes 
permissible or non-permissible research, (c) monitoring and periodically reviewing ongoing 
research, and (d) overseeing the provenance of the human pluripotent stem cell lines used 
in Category 2 Research (see section 2.1.5.2). 
2.1.4 
The specialized scientific and ethics oversight process should be conducted by qualified 
scientists, ethicists, legal and regulatory experts, and community members who are not 
directly engaged in the research under consideration. For additional information please 
see the explanation in Section 2.1.4 of the ISSCR Guidelines.   
2.2 
To ensure that human embryo and related stem cell research is proceeding with due 
consideration, to ensure consistency of research practices among scientists globally, and 
to specify the types of scientific projects that should be subject to review, the research 
review and oversight process should use the three categories described in this section. 
2.2.1.1 
Research involving the transfer of human stem cells or their direct neural and/or glial 
derivatives into the central nervous systems of postnatal animal hosts requires review by 
institutional animal research oversight committees supplemented by reviewer expertise in 
stem cell or developmental biology. (ISSCR Guidelines, 2006; Academy of Medical 
Sciences, 2011). Such oversight should weigh the potential benefits of the research and 
should utilize available baseline non-human animal data grounded in rigorous scientific 
knowledge or reasonable inferences and involve a diligent application of animal welfare 
principles. 
2.2.2.1 
Given advancements in human embryo culture, and the potential for such research to 
yield beneficial knowledge that promotes human health and well-being, the ISSCR calls for 
national academies of science, academic societies, funders, and regulators to lead public 
conversations touching on the scientific significance as well as the societal and ethical 
issues raised by allowing such research. Should broad public support be achieved within a 
jurisdiction, and if local policies and regulations permit, a specialized scientific and ethical 
oversight process could weigh whether the scientific objectives necessitate and justify the 
time in culture beyond 14 days, ensuring that only a minimal number of embryos are used 
to achieve the research objectives. 
2.2.2.2 
Chimeric embryo and in utero research described in ‘Category 2, i’ (see above) should 
proceed for the minimum time necessary to achieve the scientific aim. This research must 
proceed incrementally, stopping at well-defined timepoints to assess the degree and 
scope of chimerism during development before proceeding to full gestation, if full 
gestation is among the well-justified goals of the research. To avoid unpredictable and 
widespread chimerism, researchers should endeavor to use targeted chimerism strategies 
to limit chimerism to a particular organ system or region of the gestating chimeric animal. 
2.2.2.3 
Further research should be undertaken to refine and assess the safety and efficacy of 
Mitochondrial Replacement Techniques (MRT), including minimizing a) the risk of 
mitochondrial carryover and b) disruptions to the interaction between mitochondrial and 
nuclear genomes. In addition, further research on polar body transfer techniques and the 
use of mitophagy or genome editing is needed to reduce or eliminate pathogenic 
 
 
mitochondrial DNA. Such research should be subject to review by a specialized oversight 
process as Category 2 Research (Section 2.1.5.2). 
2.2.3.1 
Until there is further scientific clarity regarding how to achieve desired genetic alterations, 
additional evidence for safety, and wider discussion and consensus on ethics (i.e., whether 
it should be done and, if so, under which circumstances), any attempt to edit the 
mitochondrial genome or modify the nuclear genome of human embryos for the purpose 
of human reproduction is premature and should not be permitted at this time (see Section 
2.2.3A, Category 3A, a).  
2.3.1 
The review process for the procurement of human cells and tissues should be predicated 
on the source of the material and its intended use as described in the three tiers: 1) 
banked and historical cell lines; 2) fresh human somatic cells and tissues; and 3) gametes 
and embryos.   
2.3.2.1 
Embryos, fetal tissue, and other cells and tissues should be used in research only if 
voluntary informed consent was obtained from the donors before the research 
commences. The informed consent process should be robust and document the prospect 
of therapeutic and commercial applications as well as the potential research uses, such as 
the creation of hESCs, iPSCs, other immortalized cell lines, embryos, and gametes. In the 
case of fetal tissue, consent from the woman donating the tissue is sufficient.  In the case 
of embryos made with donor gametes, this consent should be obtained from the gamete 
donors and the party(ies) with authorization to donate the embryo.     
2.3.2.2 
Informed consent for research use must be distinct from informed consent for clinical 
treatment.  
2.3.2.3 
Review of procurement protocols must ensure that cell and tissue donors are adequately 
informed about the specific aspects of their voluntary research participation. 
2.3.2.4 
Researchers should develop a policy that states whether and how incidental findings will 
be provided to cell and tissue donors. This policy must be explained during the informed 
consent process. Cell and tissue donors should be able to choose whether they wish to 
receive incidental findings, if any. Reporting findings with relevance to public health may 
be required by law in certain jurisdictions. 
2.3.2.5 
Researchers are encouraged to discuss the potential for genomic sequencing to connect 
de-identified cells and tissues to donors and their relatives during the informed consent 
process for the donation. 
2.3.3.1 
Research oversight committees must authorize all proposals to reimburse for out-of-
pocket expenses to donors of embryos, sperm, or somatic cells. 
2.3.3.2 
For the provision of oocytes for research, when oocytes are collected outside the course of 
clinical treatment, compensation for non-financial burdens should not constitute an undue 
inducement. 
2.4.1 
Proposals for derivations of new hESC lines should be scientifically justified and executed 
by scientists with appropriate expertise. A clear, detailed outline for banking new lines 
should be incorporated into derivation proposals. Whenever feasible, the distribution of 





National and international repositories should accept deposits of newly derived stem cell 
lines to preserve them, maintain them to a high standard, and ensure their authenticity. 
Repositories are encouraged to distribute them internationally to enable their 
dissemination. Researchers are encouraged to deposit data on stem cell lines into 
registries.  
2.4.3 
Documentation of the provenance of stem cell lines is critical if the cell lines are to be 
widely employed in the research community. Provenance must be easily verifiable by 
access to relevant material transfer agreements and data demonstrating the identity of 
the cell line and uses allowed under the original informed consent. If a cell line has the 
potential to be used clinically, researchers are encouraged to provide information on the 
materials used for derivation and expansion.  
2.4.4 
Institutions engaged in human stem cell research performed with public funding are 
encouraged to develop procedures whereby researchers are granted access to research 
materials for scientifically and ethically appropriate purposes, as determined under these 
guidelines and applicable laws. 
2.5.1 
These guidelines should be upheld and enforced through standards of academic, 
professional, and institutional self-regulation. 
3.1.1 
Stem cells, cells, and tissues that are substantially manipulated or used in a non-
homologous manner must be proven safe and effective for the intended use before being 
marketed to patients or incorporated into standard clinical care.  
3.2.1.1 
Donors of cells for allogeneic use should give written and legally valid informed consent 
that covers, where applicable, terms for potential research and therapeutic uses, 
disclosure of incidental findings, potential for commercial application, and issues specific 
to the type of intervention under development. 
3.2.1.2 
Donors for allogeneic stem cell-based interventions should be screened and tested for 
infectious diseases and other risk factors, in compliance with applicable regulatory 
guidelines (see Recommendation 2.4.3). 
3.2.2.1 
All reagents and processes should be subject to quality control systems and standard 
operating procedures to ensure the quality of the reagents and consistency of protocols 
used in manufacturing. Manufacturing should be performed under GMP conditions when 
possible or mandated by regulation.  However, in early-stage clinical trials it is understood 
that GMPs may be introduced in a phase appropriate manner in some regions. 
3.2.2.2 
The oversight and review of cell processing and manufacturing protocols should be 
rigorous, and consider the manipulation of the cells, their source and intended use, the 
nature of the clinical trial, and the research subjects who will be exposed to them. 
3.2.2.3 
Human or chemically defined components should be used in the culture or preservation of 
cells whenever possible.  
3.2.2.4 
All reagents used in manufacturing stem cell-derived therapeutics should be of the highest 
quality available.  
3.2.2.5 
Criteria for in process and release specifications should be developed during the 
regulatory review process. Culture-acquired genetic abnormalities may be a significant risk 
and should be part of in process and/or final product testing for stem cell products that 




Criteria for release of cells should include the assessment of off-target cells, using the 
most sensitive assays possible.  
3.3.1.1 
Preclinical research into stem cell-based interventions involving animals should adhere to 
the principles of the three Rs: reduce numbers, refine protocols, and replace animals with 
in vitro or non-animal experimental platforms whenever possible. 
3.3.1.2 
Early phase human studies should be preceded by a rigorous demonstration of safety and 
efficacy in preclinical studies. These preclinical studies can include in vitro and in vivo 
modeling.  
3.3.1.3 
All preclinical studies testing safety and efficacy should be designed in ways that support 
precise, accurate, and unbiased measures of potential clinical utility. In particular, studies 
designed to inform trial initiation should have high internal validity; they should be as 
representative as possible of clinical scenarios they are intended to model, and they 
should be replicated. 
3.3.1.4 
Preclinical studies should assess both male and female animals in safety and efficacy 
testing unless there is a scientifically valid reason not to do so. 
3.3.2.1 
Cells to be employed in clinical trials must first be rigorously characterized to assess 
potential toxicities through studies in vitro and, where possible, for the clinical condition 
and tissue physiology to be examined in animal models. 
3.3.2.2 
Risks for tumorigenicity must be rigorously assessed for any stem cell-based product, 
especially if cells are extensively manipulated in culture, genetically modified, or when 
derived from a pluripotent source. 
3.3.2.3 
For all stem cell-based products, whether injected locally or systemically, researchers 
should perform detailed and sensitive biodistribution studies of cells. 
3.3.2.4 
Before launching high-risk trials or studies with many components, researchers should 
establish the safety and optimality of other intervention components, like devices or co-
interventions such as surgeries. 
3.3.2.5 Researchers should adopt practices to address long-term risks in preclinical studies. 
3.3.2.6 
Researchers should comprehensively investigate the type, extent and genomic distribution 
of introduced genetic alterations as well as their potential adverse effects on the genome 
and the biological properties of the treated cells at short and long-term time points. 
3.3.2.7 
Researchers, sponsors, and regulators should take advantage of the potential for using 
stem cell-based systems to enhance the predictive value of preclinical toxicology studies. 
3.3.3.1 
Trials should generally be preceded by compelling preclinical evidence of clinical utility in 
well-designed studies. Animal models suited to the clinical condition and the tissue 
physiology should be used, unless there is evidence of efficacy using similar products 
against similar human diseases, or if it is not feasible to establish appropriate or predictive 
animal models. 
3.3.3.2 
Appropriate animal models should be selected which allow the assessment of efficacy and 
safety of the stem cell-based intervention. Safety testing should include assessment of the 
delivery procedure or surgical technique used for implantation of the cells. 
3.3.4.1 
Sponsors, researchers, and clinical investigators should publish preclinical studies in full 
and in ways that enable an independent observer to interpret the strength of the evidence 




All research involving clinical applications of stem cell-based interventions must be subject 
to prospective review, approval, and ongoing monitoring by independent human subjects 
research review committees. 
3.4.1.2 
The review process for stem cell-based clinical research should ensure that protocols are 
vetted by independent experts who are competent to evaluate (a) the in vitro and in vivo 
preclinical studies that form the basis for proceeding to a trial and (b) the design of the 
trial, including the adequacy of the planned endpoints of analysis, statistical 
considerations, and disease-specific issues related to human subjects protection. 
3.4.2.1 
Risks should be identified and minimized, unknown risks acknowledged, and potential 
benefits to subjects and scientific understanding estimated. Sponsors should be able to 
justify research with human subjects in terms of likely risk and benefit based on evidence 
from preclinical studies and the published literature.  
3.4.2.2 
Initiation of clinical trials should be supported by a systematic appraisal of evidence 
supporting the intervention and the current unmet need for treatment of the disease or 
disorder. 
3.4.2.3 
Stem cell-based interventions must be aimed toward being clinically competitive with 
existing therapies or meeting a unique therapeutic demand. Being clinically competitive 
necessitates having reasonable evidence that existing treatments are less than optimal or 
pose burdens that may be overcome should the stem cell-based intervention prove to be 
safe and effective. 
3.4.2.4 
Individuals who participate in clinical stem cell research should be recruited from 
populations that are in a position to benefit from the results of this research. Groups or 
individuals must not be excluded from the opportunity to participate in clinical stem cell 
research without rational scientific justification. Unless scientifically inappropriate, trials 
should strive to proportionally include women, as well as men, and members of all ethnic 
groups.  
3.4.2.5 
Informed consent must be obtained from potential human subjects or their legally 
authorized representatives. Reconsent of subjects must be obtained if substantial changes 
in risks or benefits of a study intervention are identified or alternative treatments emerge 
during the research. 
3.4.2.6 
When human research participants lack the capacity to provide valid informed consent, 
when no other reasonably effective options exist, and the risks from study procedures 
should be limited to no greater than a minor increase over the minimal risk unless the risks 
associated with the intervention are exceeded by the prospect of therapeutic benefit. A 
legally authorized representative or substitute decision-maker should help make decisions 
that are in the patient’s interest. 
3.4.2.7 
Prior to obtaining consent from potential adult subjects who have diseases or conditions 
that are known to affect cognition, their capacity to consent should be assessed formally. 
3.4.2.8 Research teams must protect the privacy of human subjects. 
3.4.2.9 
Patient-sponsored and pay-to-participate trials pose challenges for ensuring scientific 
merit, integrity, and priority as well as fair selection of study participants. Accordingly, 
charging individuals to participate in clinical trials should only be permitted when such 
 
 
studies are compliant with applicable national regulations and are approved and 
supervised by a rigorous independent review body, such as an institutional review board.  
3.4.3.1 All trials should be prospectively registered in public databases. 
3.4.3.2 
Investigators should report adverse events, including their severity and potential causal 
relationship with the experimental intervention. 
3.4.3.3 
Researchers should promptly publish results regardless of whether they are positive, 
negative, or inconclusive. Studies should be published in full and according to international 
reporting guidelines, including registration in the public databases. 
3.4.4.1 
Consent procedures in any prelicensure phase, but especially early phase trials of stem 
cell-based interventions, should work to dispel potential research subjects’ overestimation 
of benefit and therapeutic misconception. 
3.4.4.2 
In general, initial tests of a novel strategy should be tested under lower-risk conditions 
before escalating to higher risk study conditions even if they are more likely to confer 
therapeutic benefit. 
3.4.4.3 Researchers should take measures to maximize the scientific value of early phase trials. 
3.4.5.1 
Clinical research should compare new stem cell-based interventions against the best 
therapeutic approaches that are currently or could be made reasonably available to the 
local population. 
3.4.5.2 
Where there are no proven effective treatments for a medical condition and stem cell-
based interventions involve invasive delivery, it may be appropriate to test them against 
historical controls, placebo, or sham comparators, assuming early experience has 
demonstrated the feasibility and safety of the particular intervention. 
3.4.6.1 
A data-monitoring plan is required for clinical studies. When deemed appropriate, 
aggregate updates should be provided at predetermined times or on-demand. Such 
updates should include adverse event reporting and ongoing statistical analyses if 
appropriate. Data monitoring personnel and committees should be independent from the 
research team. 
3.4.6.2 
Given the potential for transplanted cellular products to persist indefinitely and depending 
on the nature of the experimental stem cell-based intervention, subjects should be 
advised to undergo long-term health monitoring. Long-term follow-up is mandated in 
some countries, often for the use of gene therapies or xenotransplants. Additional 
safeguards for ongoing research subject privacy should be provided. Subject withdrawal 
from the research should be made in an orderly fashion to promote physical and 
psychological welfare. 
3.4.6.3 
To maximize the opportunities for scientific advance, research subjects or surviving next of 
kin in stem cell-based intervention studies should be asked for consent to a partial or 
complete autopsy in the event of death to obtain information about cellular implantation 
and functional consequences at some point in the trial. Requests for an autopsy must 
consider cultural and familial sensitivities and be conducted in a respectful and 
compassionate manner. Researchers should strive to incorporate a budget for autopsies in 
their trials and develop a mechanism to ensure that these funds remain available over 




The clinical use of genetically altered (including genome-edited) somatic stem cells should 
be reserved for the treatment or correction of severe disease and disability. Due to the 
inherent risks, these products should comply with established policies and regulations for 
genome editing and cell-based products.  
3.4.8.1 
Mitochondrial Replacement Techniques (MRT) should be offered only in the context of 
clinical investigation that is subject to strict regulatory oversight, limited to patients at high 
risk of transmitting serious mitochondrial DNA-based diseases to their offspring, when no 
other treatments are acceptable, and where long-term follow-up is feasible. International 
data sharing arising from initial uses is essential to help inform the field and ensure its 
appropriate use. 
3.4.8.2 
There are inadequate clinical and preclinical data to justify the use of MRT to treat 
unexplained infertility associated with poor oocyte/embryo quality in women; therefore, it 
is recommended that this not be an intervention at this time..  
3.4.8.3.1 
Substantial preclinical research is needed to minimize the potential harm associated with 
clinical applications involving germline genome editing; therefore, any attempt to modify 
the nuclear genome of human embryos for the purpose of reproduction is premature and 
should not be permitted at this time (see Section 2.1.3.3, Category 3A, a).  
3.4.8.3.2 
If the technical and safety challenges associated with human germline genome editing are 
resolved (see Recommendations 2.1.4 and 3.4.8.3.1), any applications for the initial clinical 
use of human germline genome editing should be evaluated on a case-by-case basis. This 
evaluation needs to consider not just the scientific methods, but also the societal and 
ethical issues associated with the proposed use.   
3.4.8.3.3 
A comprehensive regulatory and ethical framework for overseeing germline genome 
editing must be established before any first-in-human clinical applications are considered. 
This framework should build on the existing regulatory frameworks for new 
biotechnologies, the practice of medicine, and the principles outlined in these guidelines 
(see Section 3.3 and 3.4).  
3.4.8.3.4 
Regulators, research funders, and academic and medical societies should seek to prevent 
the premature or unethical clinical uses of germline genome editing unless and until the 
safety, ethical, and societal issues associated with the clinical use of germline genome 
editing are resolved.  
3.4.9.1 
Clinical research involving in utero stem cell-based interventions or genome editing 
involves risks to both the pregnant woman and the future child, and should be undertaken 
only when it offers the prospect of a benefit greater than that of post-natal interventions, 
does not pose excessive risk to the pregnant woman, and where there is institutional 
capacity for autopsy (in the case of miscarriage or stillbirth) or follow-up (in the case of live 
birth).   
3.5.1 
The clinical use of unproven stem cell-based interventions should be limited to well-
regulated clinical trials and medical innovations compliant with these guidelines 
(Recommendation 3.5.2) and local laws, policies, and regulations. Government authorities 
and professional organizations should establish and strictly enforce policies and 




Given the many uncertainties surrounding medical innovations involving stem cells and 
their direct derivatives, this pathway is rarely ethically and scientifically justifiable and 
should be limited to a very small number of patients and restricted to a) the off-label use 
of authorized therapies (see Recommendation 3.5.3), b) unproven interventions provided 
through expanded access pathways (see Recommendation 3.5.4), or c) minimally 
manipulated stem cell based interventions for homologous uses. Such interventions 
should only be provided to patients according to the highly restrictive provisions outlined 
in this section and the other referenced recommendations. 
3.5.3 
Off-label uses of stem cell-based interventions should be employed with particular care, 
given uncertainties often associated with off-label uses generally and associated with stem 
cell-based interventions specifically. 
3.5.4 
Pre-approval access to experimental stem cell-based interventions should be limited to 
well-regulated programs that require prior authorization from national regulators. 
3.6.1.1 
The introduction of novel products into routine clinical use should be dependent on the 
demonstration of substantial evidence of effectiveness in appropriately powered, well-
controlled clinical trials, with statistically significant findings. 
3.6.1.2 
When evaluating new interventions for rare diseases or life-threatening medical 
conditions, regulators should consider the acceptable balance of risk and clinical benefit 
appropriate to the medical condition and patient population for which new treatments are 
designed. All approval pathways should require substantial evidence of safety and 
effectiveness before products are marketed to patients.  
3.6.1.3 
In jurisdictions with conditional approval mechanisms, regulators must ensure there is a 
robust post-market surveillance system whereby regulators have the capacity and power 
to remove products from the market as appropriate. 
3.6.1.4 
In jurisdictions with existing approval pathways for orphan or rare diseases, those 
pathways should be used to facilitate the development of stem cell-based interventions.  
3.6.1.5 
Developers, manufacturers, providers, and regulators of stem cell-based interventions 
should continue to systematically collect and report data on safety, efficacy, and utility 
after they enter clinical use. 
3.6.1.6 
Registries of specific patient populations should be used to provide valuable data on the 
natural history and progression of diseases that can support the development of 
meaningful endpoints, biomarkers, and outcomes measures to facilitate the development 
of new products. Furthermore, patient registries are useful tools for monitoring adverse 
events after regulators have approved a product for routine clinical use. However, 
registries should not be substituted for well-regulated randomized controlled clinical trials 
designed to evaluate the safety and efficacy of complex products like stem cell and gene-
based interventions. 
3.6.1.7 
Provision and use of equipment and commercial kits for cell and gene-based interventions 
in humans should be limited to settings with an appropriate level of regulatory oversight 
to ensure their safe and responsible use. 
3.6.2.1 
Stem cell-based interventions should be developed to deliver health and economic value 




Payers, and healthcare systems should work with developers of stem cell interventions, 
patients, and regulators to establish processes to evaluate their health and economic 
value, including conditional pathways. 
3.6.2.3 
Developers, funders, providers, and payers should work to ensure that cost of treatment 
does not prevent patients from accessing stem cell-based interventions for life-
threatening or seriously debilitating medical conditions. 
4.1 
The stem cell research community should promote accurate, current, balanced, and 
responsive public representations of stem cell research. 
4.2 
When describing clinical trials in the media or in medical communications, investigators, 
sponsors, and institutions should provide balance and not emphasize statistically 
significant secondary results when pre-specified primary efficacy results are not 
statistically significant.  
4.3 
The provision of information to patients considering stem cell-based interventions must be 
consistent with the primacy of patient welfare, scientific and ethical integrity. 
5.1 
Researchers, industry, and regulators should work towards developing and implementing 
standards on design, conduct, interpretation, preclinical safety testing, and reporting of 
research in stem cell science and medicine. 
5.2 
The ISSCR guidelines should be periodically revised to accommodate scientific advances, 
new challenges, and evolving social priorities. 
 
Table 3 Legend: A compilation of all the recommendations from the ISSCR Guidelines for Stem 
Cell Research and Clinical Translation 
 
Table 4: Summary of Significant Changes in the 2021 ISSCR Guidelines for Stem Cell Researhc 





1. Renames EMRO review process to  a “specialized oversight process capable of evaluating the 
unique aspects of the science and the associated ethics issues.”  




CATEGORIES OF RESEARCH  
1. Divides Category 1 and 3 into two subcategories each. The changes to the research categories 
are noted below.  
o 1A – Exempt from specialized oversight process (review by existing oversight review 
processes). 
§ Most in vitro pluripotent stem cell research [unchanged, previously Category 
1] 
§ Fetal tissue [new for clarity] 
§ Research that involves transplanting human cells into non-embryo animals 
[new for clarity] 
§ Organoids [new] 
o 1B – Reportable, but not typically subject to further or ongoing review. 
§ In vitro culture of chimeric embryos (with human cells) 
§ Non-integrated stem cell-based embryo models [formerly category 2] 
§ In vitro gametogenesis without fertilization or generation of embryos [new] 
§ In vitro chimeric embryo research [new] 
o 2 – Review through specialized oversight process. 
§ Procurement of human gametes, embryos, etc. [unchanged] 
§ Derivation of cell lines from human embryos [unchanged] 
§ In vitro genetic alteration of human embryos or gametes [unchanged] 
§ Integrated stem cell-based human embryo models for the minimum time 
necessary to achieve scientific objective [previously limited to 14 days or 
formation of primitive streak] 
§ Transferring human embryos following MRT into a human uterus [new] 
§ Transferring chimeric embryos into a non-human uterus, excluding transfer 
into greater and lesser apes, which is prohibited [new] 
o 3A – Research activities currently not permitted because it is currently unsafe or 
raises unresolved ethical issues. 
§ Germline genome editing of the nuclear DNA of a human embryo followed by 
transfer to a uterus [unchanged, previously Category 3] 
§ Germline genome editing of the mitochondrial DNA of a human embryo 
followed by transfer to a uterus [new for clarity] 
§ Using gametes differentiated from human stem cells for reproduction [new] 
o 3B – Prohibited research activities because of a broad international consensus that 
such research lacks a compelling scientific rationale or is widely considered to be 
unethical.  
§ Transferring stem cell-based human embryo models to a uterus [unchanged, 
previously Category 3] 
§ Transferring an IVG-derived human embryo into the uterus of an animal host 
[new] 
§ Human reproductive cloning [unchanged, previously Category 3] 
 
 
§ Breeding human-animal chimeras that may have or have the potential to 
form human gametes [unchanged, previously Category 3] 
§ Transferring human-animal chimeric embryos to a human or ape uterus [new] 
o New recommendation on 14-day rule: Given advancements in human embryo 
culture, and the potential for such research to yield beneficial knowledge that 
promotes human health and well-being, the ISSCR calls for national academies of 
science, academic societies, funders, and regulators to lead public conversations 
touching on the scientific significance as well as the societal and ethical issues raised 
by allowing such research. Should broad public support be achieved within a 
jurisdiction, and if local policies and regulations permit, a specialized scientific and 
ethical oversight process could weigh whether the scientific objectives necessitate 
and justify the time in culture beyond 14 days, ensuring that only a minimal number 
of embryos are used to achieve the research objectives. 
 
 
PROCUREMENT OF CELLS AND TISSUES / DERIVATION OF STEM CELL LINES  
1. New three-tiered review system to streamline the review process for the procurement of 
banked and historical cell lines, while maintaining the rigorous review process for the 
procurement of embryos and gametes for stem cell research.  
2. Updated recommendations on the derivation and banking of new lines to facilitate the 
development of stem cell-based products.  
 
CLINICAL TRANSLATION 
1. Adopts international standards for defining stem cell-based products as drugs or ATMPs if 
such products have been substantially manipulated or are provided for non-homologous uses. 
This standard broadly aligns the Guidelines with the regulations from U.S. FDA, EMA, and 
Australia’s TGA.  
2. Includes a new recommendation on sex as a biological variable. 
3. Strengthens the recommendation on patient registries to clarify their use as a tool for disease 
histories and tracking long-term patient outcomes. The recommendation also notes that 
registries are not adequate substitutes for randomized controlled trials to demonstrate the 
safety and efficacy of products for marketing authorizations.  
4. Includes a new recommendation to forcefully caution against the premature 
commercialization of unproven stem cell-based interventions.  
5. Narrows the types of stem cell-based products eligible for the medical innovation pathway 
that is aligned with international regulatory standards, including the U.S. FDA.  
6. Includes new recommendations on regulations authorizing stem cell-based products, 
including the demonstration of substantial evidence of effectiveness in appropriately 
powered, well-controlled clinical trials, with statistically significant findings.  
7. Supports the use of accelerated approval pathways based on surrogate or intermediate 
endpoints.  
8. Encourages robust post-market surveillance systems in jurisdictions with conditional approval 
pathways.  
9. Encourages health systems and payers to establish a process for evaluating the health and 





1. New recommendation on somatic genome editing that reserves the clinical use of genetically 
altered (including genome-edited) somatic stem cells for the treatment or correction of 
severe disease and disability. 
2. New recommendations on MRT that encourage more research to refine and assess of the 
safety and efficacy of MRT.  
3. Recommends limiting the clinical use of MRT to those at high risk of transmitting serious 
mitochondrial DNA-based diseases to their offspring and when no other treatments are 
acceptable.  
4. Recommends that there is no use of MRT for unexplained infertility associated with poor 
oocyte/embryo quality in women due to inadequate pre-clinical data. 
5. New Recommendations on Heritable Germline Genome Editing. 
o Prohibits clinical applications involving germline genome editing and encourages 
preclinical research to minimize the potential harm associated with such applications.  
o Provides guidance for initial clinical uses of human germline genome editing once the 
technical, safety, and ethical issues are resolved, including a case-by-case evaluation 
of scientific methods and the societal and ethical issues associated with any proposed 
use.   
o Encourages the development of a comprehensive regulatory and ethical framework 
for overseeing germline genome editing that builds on the existing regulatory 
frameworks for new biotechnologies, the practice of medicine, and the principles in 
the ISSCR Guidelines.  
6. New guidance on in utero genome and stem cell-based interventions: Clinical research 
involving in utero stem cell-based interventions or genome editing involves two patients, the 
pregnant woman and the future child, and should be undertaken only when it offers the 
prospect of a benefit greater than that of post-natal interventions, does not pose excessive 
risk to the pregnant woman, and where there is institutional capacity for autopsy (in the case 
of miscarriage or stillbirth) or follow-up (in the case of live birth).   
 
 
Legend: A summary of the significant changes between the 2016 and 2021 ISSCR Guidelines for 
Stem Cell Research and Clinical Translation. 
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